Literature DB >> 1660294

Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours.

B Casslén1, B Gustavsson, B Astedt.   

Abstract

The binding of 125I-labelled urokinase plasminogen activator (uPA) to cell membranes of ovarian tumours was characterised. Binding was fast, specific to HMW-uPA, and saturated at low concentration [1.5 (range 1.2-1.6) nmol/l]. Scatchard analysis suggested a single class of binding sites with Kd 1.1 (0.9-1.3) nmol/l. These data indicate the presence of a specific cell membrane receptor for uPA in ovarian tumours, whose characteristics are similar to those reported for uPA receptors in other tissues. Endogenously occupied receptors were uncovered by exposing the membranes to acid conditions (pH 2) before assay, thereby allowing quantitation of the total amount of receptor. uPA receptors were assayed in 10 malignant and 6 benign epithelial ovarian tumours. The total number of receptors was higher in the malignant tumours. This was secondary to increases of both free and occupied receptors. We conclude that this reflects the biological function of cell surface bound plasminogen activation in tumour growth and spread.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1660294     DOI: 10.1016/0277-5379(91)90028-c

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.

Authors:  Hilary A Kenny; Payton Leonhardt; Andras Ladanyi; S Diane Yamada; Anthony Montag; Hae Kyung Im; Sujatha Jagadeeswaran; David E Shaw; Andrew P Mazar; Ernst Lengyel
Journal:  Clin Cancer Res       Date:  2010-12-13       Impact factor: 12.531

2.  Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.

Authors:  Kyung Hee Lee; Myung Soo Hyun; Jae-Ryong Kim
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

3.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

4.  Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion.

Authors:  H Kobayashi; H Shinohara; H Ohi; M Sugimura; T Terao; M Fujie
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

5.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.

Authors:  C Festuccia; V Dolo; F Guerra; S Violini; P Muzi; A Pavan; M Bologna
Journal:  Clin Exp Metastasis       Date:  1998-08       Impact factor: 5.150

7.  Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.

Authors:  S N Wagner; M J Atkinson; S Thanner; C Wagner; M Schmitt; O Wilhelm; M Rotter; H Höfler
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

8.  Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.

Authors:  Roberta Bacchiocchi; Corrado Rubini; Elisa Pierpaoli; Giulia Borghetti; Pasquale Procacci; Pier Francesco Nocini; Andrea Santarelli; Romina Rocchetti; Domenico Ciavarella; Lorenzo Lo Muzio; Francesca Fazioli
Journal:  BMC Cancer       Date:  2008-08-01       Impact factor: 4.430

Review 9.  Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications.

Authors:  Morten Persson; Andreas Kjaer
Journal:  Clin Physiol Funct Imaging       Date:  2013-04-03       Impact factor: 2.273

10.  Increased cell-surface urokinase in advanced ovarian cancer.

Authors:  H Kobayashi; N Moniwa; M Sugimura; H Shinohara; H Ohi; T Terao
Journal:  Jpn J Cancer Res       Date:  1993-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.